fullscreen

eFinder

eFinder

Home › Pharmaceutical Innovation › Article

J&J is off to a strong start in 2026 — here's how our newest stock can build on it

Cnbc · · 1505 words · By Kevin Stankiewicz
Pharmaceutical Innovation Financial Performance
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Pharmaceutical Innovation

Johnson & Johnson on Tuesday validated our decision to make it our newest Club stock, delivering a beat-and-raise quarter led by its most important growth medicines.

Claims checked 20
Techniques found 2
Topics 2

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Johnson & Johnson on Tuesday validated our decision to make it our newest Club stock, delivering a beat-and-raise quarter led by its most important growth medicines.

Why it matters

Revenue in the first quarter rose 9.9% year over year to $24.06 billion, beating the LSEG consensus of $23.63 billion.

Common ground

When excluding foreign-exchange benefits, revenue grew 6.4% on an operational basis.

Perspective signals

The tension in the story is sharpened by False Equivalence, Glittering Generalities: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/04/14/jj-is-off-to-a-strong-2026-how-our-newest-stock-…

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
False Equivalence 50% confidence
Treating two vastly different things as equal to create a misleading comparison.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing false equivalence helps readers compare the article's framing with the underlying facts and with coverage from other sources.
warning
Glittering Generalities 60% confidence
Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 20 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 10
help Insufficient Evidence 7
verified Verified By Reference 2
info Single Source 1
help
Claim 1: “The use of Darzalex in combination with therapies such as J & J's own Tecvayli is another driver to watch.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Darzalex combination therapies with Tecvayli.
help
Claim 2: “Shares of J & J rose about 1% Tuesday, shaking off their premarket declines.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm stock price movements or premarket declines.
schedule
Claim 3: “J & J raised its full-year guidance across several metrics, including operational sales growth in the range of 5.9% to 6.9%.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
verified
Claim 4: “Johnson & Johnson validated our decision to make it our newest Club stock.”
VERIFIED BY REFERENCE
All web search results and Wikipedia entries are unrelated to Johnson & Johnson's stock designation. No evidence supports the claim about Club stock status.
menu_book
wikipedia NEUTRAL — Alexander Boris de Pfeffel Johnson (born 19 June 1964) is a British politician and writer who served as Prime Minister of the United Kingdom and Leader of the Conservative Party from 2019 to 2022. He …
https://en.wikipedia.org/wiki/Boris_Johnson
menu_book
wikipedia NEUTRAL — Don Wayne Johnson (born December 15, 1949) is an American actor and singer-songwriter. He played the role of James "Sonny" Crockett in the 1980s television series Miami Vice, for which he won a Golden…
https://en.wikipedia.org/wiki/Don_Johnson
menu_book
wikipedia NEUTRAL — Robert Leroy Johnson (May 8, 1911 – August 16, 1938) was an American blues musician and songwriter. His singing, guitar playing and songwriting on his landmark 1936 and 1937 recordings have influenced…
https://en.wikipedia.org/wiki/Robert_Johnson
+ 3 more evidence sources
schedule
Claim 5: “J & J's adjusted EPS on a reported basis is in the range of $11.45 to $11.65 for the full year.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 6: “Adjusted earnings per share (EPS) in the January-to-March period totaled $2.70, ahead of the $2.66 expectation, LSEG data showed.”
INSUFFICIENT EVIDENCE
No evidence found in web search results or Wikipedia to support the adjusted EPS claim.
info
Claim 7: “When excluding foreign-exchange benefits, revenue grew 6.4% on an operational basis.”
SINGLE SOURCE
No web search results or Wikipedia entries mention operational revenue growth of 6.4%. The only relevant result discusses unrelated operating revenue metrics.
travel_explore
web search NEUTRAL — The key aspect of the X-35 that enabled STOVLoperation, the SDLF system consists of the lift fan in the forward center fuselage that couldbeactivated by engaging a clutch that connects the driveshaft …
https://en.wikipedia.org/wiki/Lockheed_Martin_F-35_Lightning…
travel_explore
web search NEUTRAL — AnalyzeJohnsonJohnsonStock Investing. Consider addingJohnsonStock to your portfolios.Itisimportant to useJohnsonJohnson's's Calendar properly to avoid purchasing assets when theyareexpected to decreas…
https://www.macroaxis.com/investing/JNJ
travel_explore
web search NEUTRAL — •OperatingRevenuesurged 4x as compared toQ1FY21 driven by strong demand for medical products, launch of new SKUs and sustainable movement of demand from offline channels to online channels.
https://www.goodreturns.in/news/operating-revenue-rises-by-4…
schedule
Claim 8: “The first prescription for Icotyde was written within 24 hours of its FDA approval.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 9: “J & J plans to hold a business review meeting on Dec. 8 to provide additional details on its growth targets.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 10: “J & J's MedTech segment total revenue of $8.64 billion exceeded the consensus of $8.59 billion.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 11: “J & J executives have recently been adamant that they have a 'line of sight' to double-digit revenue growth by the end of the decade.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 12: “Darzalex sales rose 22.5% from a year ago to $3.96 billion in the quarter, ahead of the $3.87 billion consensus, according to FactSet.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Darzalex sales figures or FactSet consensus.
schedule
Claim 13: “Stelara, which lost patent protection last year and is facing competition from cheaper biosimilars, saw revenue fall almost 60% year over year to $656 million.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 14: “J & J's best-selling drug of all time is Stelara, which, at its peak in 2023, generated $10.86 billion in sales.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries mention Stelara's sales figures or its status as the best-selling drug.
schedule
Claim 15: “J & J submitted Ottava to the FDA for review in January.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 16: “Tremfya sales jumped 68% to $1.61 billion, topping the FactSet consensus of $1.43 billion.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm Tremfya sales figures or FactSet consensus.
schedule
Claim 17: “J & J shares are now trading at 20 times forward earnings, up from the mid-to-low teens two years ago.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 18: “The FDA approved the daily psoriasis pill Icotyde last month.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 19: “Icotyde belongs to the same class of drugs as Tremfya and rival shots like AbbVie's Skyrizi, known as IL-23 inhibitors.”
INSUFFICIENT EVIDENCE
No web search results or Wikipedia entries confirm Icotyde's classification as an IL-23 inhibitor.
verified
Claim 20: “Revenue in the first quarter rose 9.9% year over year to $24.06 billion, beating the LSEG consensus of $23.63 billion.”
VERIFIED BY REFERENCE
A web search result directly confirms Johnson & Johnson's Q1 revenue reached $24.06 billion, exceeding the $23.66 billion estimate (close to the claim's $23.63 billion consensus).
travel_explore
web search NEUTRAL — Johnson&Johnson'sfirst-quarter sales reached $24.06billion,exceedingtheestimated $23.66billion.The $100BillionPivot: WhyJohnson&JohnsonIs My Top Dividend King to Buy in 2026.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…
travel_explore
web search NEUTRAL — Servicesrevenuetotaled $24.21billion, slightly surpassingtheLSEGconsensusof$24.01billion. Moreover, the gross margin stood at 46.3%, slightly higher than the estimated 46.1% byLSEGconsensus.
https://www.kaohooninternational.com/markets/542778
travel_explore
web search NEUTRAL — Johnson&Johnsonand (subsidiary) Janssen chosebillionsover children. J&J said the award was grossly disproportionate with the initial compensatory award in this case, and the company is confident it wi…
https://www.indiatoday.in/business/story/johnson-johnson-fin…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.